EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain

Heather J Whitaker iD, Naoma Willam, Simon Cottrell, Rosalind Goudie, Nick Andrews, Josie Evans, Catherine Moore, Utkarsh Agrawal, Katie Hassell, Rory Gunson, Jana Zitha iD, Sneha Anand und 18 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Heather J Whitaker und 29 weiteren Autor:innen. Beteiligte Einrichtung: Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Primary Health Care, Influenza A Virus, H3N2 Subtype. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Health Security Agency, Public Health Scotland, Public Health Wales.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.

Methods

End‐of‐season adjusted vaccine effectiveness (VE) estimates against sentinel primary‐care attendance for influenza‐like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.

Methods

Results In the mainland United Kingdom, end‐of‐season VE against all laboratory‐confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell‐based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).

Conclusion

The paper provides evidence of moderate influenza VE in 2022/23.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanPrimary Health CareInfluenza A Virus, H3N2 SubtypeVaccine EfficacyInfluenza B virusHumansMiddle AgedAdolescentAdultUnited KingdomAgedYoung AdultChildFemaleMaleChild, PreschoolInfluenza A Virus, H1N1 SubtypeSeasonsVaccination

Stichwörter der Autor:innen

effectivenessinfluenzavaccine

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK.
  • Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.
  • Public Health Wales Communicable Disease Surveillance Centre, Public Health Wales, Cardiff, UK.
  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
  • Wales Specialist Virology Centre, Public Health Wales Microbiology, Cardiff, UK.

ORCID-Profile: Heather J Whitaker, Jana Zitha, Gavin Jamie, Beatrix Kele

Förderung

  • UK Health Security Agency
  • Public Health Scotland
  • Public Health Wales

Zitieren

APA

Whitaker, H. J., Willam, N., Cottrell, S., Goudie, R., Andrews, N., Evans, J., Moore, C., Agrawal, U., Hassell, K., Gunson, R., Zitha, J., Anand, S., Sebastian-Pillai, P., Kalapotharakou, P., Okusi, C., Hoschler, K., Jamie, G., Kele, B., Hamilton, M., …, & Watson, C. H. (2024). End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13295

Vancouver

Whitaker HJ, Willam N, Cottrell S, Goudie R, Andrews N, Evans J, et al. End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13295

BibTeX
@article{Whitaker2024,
  author = {Whitaker, Heather J and Willam, Naoma and Cottrell, Simon and Goudie, Rosalind and Andrews, Nick and Evans, Josie and Moore, Catherine and Agrawal, Utkarsh and Hassell, Katie and Gunson, Rory and Zitha, Jana and Anand, Sneha and Sebastian-Pillai, Praveen and Kalapotharakou, Panoraia and Okusi, Cecilia and Hoschler, Katja and Jamie, Gavin and Kele, Beatrix and Hamilton, Mark and Couzens, Anastasia and Quinot, Catherine and Pheasant, Kathleen and Byford, Rachel and Marsh, Kimberly and Robertson, Chris and de Lusignan, Simon and Williams, Christopher and Zambon, Maria and McMenamin, Jim and Watson, Conall H},
  title = {End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13295}
}
Kostenlos starten →